News
Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place (PRTA)
This article was written byFollowTerry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his…
Fabrinet: Strong Performer Commands A Premium (NYSE:FN)
This article was written byFollowThe Value Investor has a Master of Science with specialization in financial markets and a decade…
Atlas Engineered Products Ltd. (APEUF) Q1 2025 Earnings Call Transcript
Atlas Engineered Products Ltd. (OTCPK:APEUF) Q1 2025 Earnings Conference Call May 27, 2025 11:00 AM ET Company Participants Jake Bouma…
John Hancock Disciplined Value International Fund Q1 2025 Commentary
This article was written byFollowA company of Manulife Investment Management, John Hancock Investment Management serves investors through a unique multimanager…
Zhihu Inc. (ZH) Q1 2025 Earnings Call Transcript
Zhihu Inc. (NYSE:ZH) Q1 2025 Earnings Conference Call May 27, 2025 8:00 AM ET Company Participants Yolanda Liu - Director…
Straumann (SAUHF) Stock: A ‘Hold’ Despite Nice Growth Numbers
This article was written byFollowThe Investment Doctor is a financial writer, highlighting European small-caps with a 5-7 year investment horizon.…
Madison Covered Call & Equity Income Fund Q1 2025 Investment Strategy Letter
This article was written byFollowMadison Investments is 100% employee-owned and has been based in Wisconsin’s capital city since its founding…
‘Straws In The Wind’: Predictions? – Weekly Blog # 890
This article was written byFollowA. Michael Lipper is a CFA charterholder and the president of Lipper Advisory Services, Inc., a…